What compounds target CDK17?

BiohacksAI has identified 32 compounds that interact with CDK17 (cyclin dependent kinase 17). Top compounds include: alvocidib, foretinib, tozasertib, ponatinib, palbociclib. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is CDK17 (cyclin dependent kinase)?

CDK17 is cyclin dependent kinase 17. It is a molecular target for 32 compounds documented in PubMed bioassay data. UniProt ID: Q00537. NCBI Gene ID: 5128.

CDK17

MOLECULAR TARGET

cyclin dependent kinase 17

UniProt: Q00537 NCBI Gene: 512832 compounds

CDK17 (cyclin dependent kinase 17) is targeted by 32 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting CDK17

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	alvocidib	4.52	91
2	foretinib	4.34	76
3	tozasertib	4.33	75
4	ponatinib	4.26	70
5	palbociclib	4.22	67
6	quizartinib	3.99	53
7	dinaciclib	3.87	47
8	nintedanib	3.61	36
9	regorafenib	3.56	34
10	bms 387032	3.47	31
11	tae 684	3.43	30
12	fedratinib	3.40	29
13	at 7519	3.33	27
14	dabrafenib	3.30	26
15	dovitinib	3.09	21
16	jnj 7706621	3.09	21
17	at 9283	3.09	21
18	lestaurtinib	3.04	20
19	pf 03758309	3.00	19
20	momelotinib	2.89	17
21	r 406	2.83	16
22	milciclib	2.77	15
23	pf 00562271	2.77	15
24	pha 665752	2.71	14
25	kw 2449	2.64	13
26	ast 487	2.56	12
27	rebastinib	2.20	8
28	decernotinib	2.20	8
29	cyc 116	2.08	7
30	rg 547	2.08	7
31	Sorafenib	1.61	4
32	indirubin	0.69	1

About CDK17 as a Drug Target

CDK17 (cyclin dependent kinase 17) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 32 compounds with documented CDK17 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

CDK17 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.